AYTU — Aytu BioPharma, Inc.

Summary of Aytu BioPharma Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Revenue: $15.2 million, down from $16.2 million in Q2 2025.
  • ADHD Portfolio: $13.2 million, slightly down from $13.8 million year-over-year and flat compared to Q1 2026.
  • Pediatric Portfolio: $1.7 million, up from $715,000 in Q1 2026 but down from $2.7 million in Q2 2025.
• Gross Margin: 63.5%, down from 66.5% in the prior year, primarily due to decreased revenue and transition-related expenses.
• Operating Expenses: $11.1 million, up from $10.2 million year-over-year, driven by ExuA launch investments.
• Net Loss: $10.6 million, or $1.05 per share, compared to a net income of $800,000 in Q2 2025.
• Adjusted EBITDA: Negative $800,000, down from positive $1.3 million in the prior year.
• Cash Position: $30 million as of December 31, 2025, down from $32.6 million at the end of Q1 2026.

2. Strategic Updates and Business Highlights

• ExuA Launch: Aytu has commercially launched ExuA, the first FDA-approved 5-HT1A agonist for Major Depressive Disorder (MDD). The launch strategy focuses on prescriber adoption and brand growth through a motivated sales team and RxConnect platform.
• Sales Strategy: The company is employing a mix of personal and non-personal promotion strategies, including a virtual sales team and targeted marketing efforts to high-volume prescribers.
• Early Performance: Over 100 doctors have prescribed ExuA within the first month, with positive early feedback from patients regarding tolerability and satisfaction.

3. Forward Guidance and Outlook

• Revenue Expectations: Aytu anticipates a gradual ramp-up in ExuA net revenue, with initial scripts expected to grow ahead of recognized revenue due to patient access strategies.
• Operational Efficiency: The initial launch budget for ExuA has been reduced from $10 million to under $8 million, indicating improved execution efficiency.
• Breakeven Point: The company estimates a quarterly breakeven revenue of approximately $17.3 million, with cash breakeven at around $16.6 million.

4. Bad News, Challenges, or Points of Concern

• Net Loss: The significant net loss and negative adjusted EBITDA reflect the financial impact of the ongoing investments in the ExuA launch and the deemphasis on the ADHD and pediatric portfolios.
• Weather Impact: Recent severe weather has affected sales representatives' productivity and prescription fulfillment, potentially hindering early launch momentum.
• Generic Competition: The entry of generic competition for Adzenys has begun to impact the ADHD portfolio, although Aytu believes its RxConnect platform will mitigate significant erosion.

5. Notable Q&A Insights

• Physician Feedback: Early prescribers of ExuA are motivated by the drug's unique mechanism of action and its potential to address unmet needs in patients who have not responded well to existing treatments.
• Salesforce Expansion: Expansion of the salesforce is not anticipated in fiscal 2026 until cash flow supports it, emphasizing a cautious approach to scaling operations.
• Direct-to-Consumer Campaign: Aytu is exploring web-based marketing strategies, including search engine optimization and social media, to raise awareness of ExuA while being compliant with regulatory requirements.

Overall, Aytu BioPharma is navigating a pivotal phase with the launch of ExuA, facing both opportunities and challenges as it seeks to establish its new product in the competitive landscape of MDD treatments.